Given the central role of PI(3,4,5)P3 in human cancer, it is not surprising that inhibition of PI(3,4,5)P3 production and/or its downstream effectors utilizing kinase inhibitors to PI3K, AKT, or mTOR (mechanistic target of rapamycin) have been utilized as promising strategies for cancer therapy (Engelman, 2009). Here, PIK3CA is linked to cancer.